Disease | ovarian cancer |
Symptom | C0027947|neutropenia |
Sentences | 3 |
PubMedID- 24657302 | Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. |
PubMedID- 24761216 | Clinical trials have reported that the incidence of febrile neutropenia in patients with ovarian cancer receiving paclitaxel and carboplatin (tc) chemotherapy is<10% , and the guidelines indicate that csfs are not needed for primary prophylaxis in these patients. |
PubMedID- 26267078 | 13 reported febrile neutropenia in 7% of patients with ovarian cancer during primary chemotherapy. |
Page: 1